Adial Pharmaceuticals, Inc. (ADIL)
|Net Income (ttm)||-9.48M|
|Trading Day||January 21|
|Day's Range||1.98 - 2.04|
|52-Week Range||1.05 - 3.03|
CHARLOTTESVILLE, VA / ACCESSWIRE / January 11, 2021 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on the dev...
Adial Pharmaceuticals Receives Notice of Allowance for Third U.S. Patent Covering AD04 for the Treatment for Opioid Use Disorder
CHARLOTTESVILLE, VA / ACCESSWIRE / January 11, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for ...
Adial Pharmaceuticals Reaches 35% Enrollment in ONWARD(TM) Pivotal Phase 3 Trial of AD04 for the Treatment of Alcohol Use Disorder
ONWARD™ Trial Remains on Track to be Fully Enrolled During Q2 2021 CHARLOTTESVILLE, VA / ACCESSWIRE / December 17, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage bio...
Adial Pharmaceuticals, a clinical-stage biopharmaceutical company, focuses on the development of treatment for addictions. Its lead product is AD04, a selective serotonin-3 antagonist for the treatment of alcohol use disorder. The company was founded in 2010 and is based in Charlottesville, Virginia.
|IPO Date |
Jul 30, 2018
William B. Stilley III, M.B.A., MBA
|Stock Exchange |
|Ticker Symbol |